Skip to main content

AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs

Newswire.ca - Fri Dec 12, 2025

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management at the point of care: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Heartflow, Inc. (NASDAQ: HTFL), CeriBell, Inc. (NASDAQ: CBLL), Medtronic plc (NYSE: MDT), and Abbott Laboratories (NYSE: ABT).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).